ArticleJournal of clinical microbiology2015
Investigations of Mycoplasma pneumoniae infections in the United States: trends in molecular typing and macrolide resistance from 2006 to 2013.
Article in Journal of clinical microbiology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 80 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
80 citing papers in PubMed, 3 syntheses or guidelines pooled it.
- Global molecular epidemiology ofEmerging microbes & infections · 2026Pooled it
- Efficacy and safety of doxycycline for severe Mycoplasma pneumoniae pneumonia in pediatric patients.Clinical and experimental medicine · 2025Pooled it
- Immunochromatography for the diagnosis of Mycoplasma pneumoniae infection: A systematic review and meta-analysis.PloS one · 2020Pooled it
- Trial
- Trial
- Mapping the Evolution of Diagnostic Research onPathogens (Basel, Switzerland) · 2026Review
- Respiratory pathogen epidemiology in the post-pandemic era: a multicenter retrospective study from Saudi Arabia.BMC infectious diseases · 2026Article
- Article
- Suspected Macrolide-RefractoryCase reports in infectious diseases · 2026Article
- Growing Threat of Macrolide-ResistantJournal of Korean medical science · 2025Review
- Mycoplasma pneumoniae MLST detected in the upsurge of pneumonia during the 2023 to 2024 winter season in the Netherlands.Scientific reports · 2025Article
- Article
- Notes from the Field: School-Based Surveillance of Mycoplasma pneumoniae Trends and Impact on School Attendance by Students and Staff Members - Missouri, Fall 2024.MMWR. Morbidity and mortality weekly report · 2024Article
- Prevention and Treatment ofInfectious diseases & immunity · 2024Article
- The molecular characteristics, diagnosis, and treatment of macrolide-resistantFrontiers in pediatrics · 2023Review
- Genotyping ofFrontiers in microbiology · 2023Article
- Epidemiology and surveillance implications of community-acquired pneumonia in children.Clinical and experimental pediatrics · 2022Article
- Unmet needs in pneumonia research: a comprehensive approach by the CAPNETZ study group.Respiratory research · 2022Review
- Identification ofThe Journal of international medical research · 2022Article
- Mycoplasma pneumoniae among Chinese Outpatient Children with Mild Respiratory Tract Infections during the Coronavirus Disease 2019 Pandemic.Microbiology spectrum · 2022Article
20 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Mycoplasma pneumoniae is a leading cause of respiratory infections, including community-acquired pneumonia (CAP). Currently, pathogen-specific testing is not routinely performed in the primary care setting, and the United States lacks a systematic surveillance program for M. pneumoniae. Documentation of individual cases and clusters typically occurs only when severe illness and/or failure to improve with empirical antibiotic therapy is observed. Outbreaks, some lasting for extended periods and involving a large number of cases, occur regularly. However, many more likely go unrecognized due to the lack of diagnostic testing and structured reporting. We reviewed data from 17 investigations of cases, small clusters, and outbreaks of M. pneumoniae infections that were supported by the Centers for Disease Control and Prevention (CDC) between 2006 and 2013. We examined 199 M. pneumoniae-positive specimens collected during this time period in order to identify trends in antimicrobial resistance and circulating types. Overall, macrolide resistance was identified in approximately 10% of M. pneumoniae infections occurring during this time period. Typing of strains revealed cocirculation of multiple multilocus variable-number tandem-repeat analysis (MLVA) and P1 types throughout this period, including diversity in types detected within individual outbreaks. Three MLVA types (4572, 3562, and 3662) accounted for 97% of the infections during the study period. A systematic surveillance program is necessary to understand the burden of M. pneumoniae disease in the United States, facilitate case and outbreak identification, and inform appropriate therapeutic and infection control strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.